Skip to main content
Log in

Rationale und rationelle Behandlung des Vorhofflimmerns

Antiarrhythmic therapy in atrial fibrillation

  • Published:
Clinical Research in Cardiology Supplements Aims and scope

Zusammenfassung

Die Möglichkeiten der antiarrhythmischen Therapie von Vorhofflimmern sind heute vielfältiger und effektiver, aber auch komplizierter als noch vor wenigen Jahren. Dies gilt gleichermaßen für die Indikation zur Therapie allgemein wie für den Entschluss zu einer bestimmten therapeutischen Maßnahme und die Kontrolle der antiarrhythmischen Behandlung selbst. Bei einer Tachyarrhythmia absoluta ist eine Normalisierung der Kammerfrequenz über den Einsatz von Calciumantagonisten, β-Blockern, Digitalis, Glykosiden oder Amiodaron zur Senkung der AV-nodalen Leitungskapazität anzustreben. Sprechen die Patienten auf die medikamentöse Therapie nicht an, steht als wirksame Maßnahme die Ablation des AV-Knotens mit konsekutiver Schrittmacherimplantation (meist VVIR-Stimulation) zur Verfügung. Bei medikamentöser Therapieresistenz und ausgeprägter Symptomatik stehen auch die präventive Schrittmachertherapie sowie kathetergestützte Ablationstechniken zu Gebote. Bei ausreichender Kenntnis der medikamentösen und interventionellen antiarrhythmischen Möglichkeiten dürften therapieresistente Formen von Vorhofflimmern und Risiken der Arrhythmiebehandlung auf ein Minimum zu reduzieren sein.

Abstract

The treatment of atrial fibrillation still remains challenging in everyday practice. After the introduction of catheter ablation, the decision making about the type in therapy became even more complex. The recently published guidelines of the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC) clearly show therapeutic approaches for different types of atrial fibrillation. The fear of thromboembolism still forces the physician to restore sinus rhythm and perform a perfect anticoagulation. Based on large studies, we are able to decide for each patient individually whether oral anticoagulation or acetylsalicylic acid/clopidolgrel are required. Future studies in a large cohort of patients are still necessary to clarify the value of interventional therapy and high quality of life despite presenting paroxysmal or persistent atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Gallagher MM, Camm AJ (1998) Classification of atrial fibrillation. Am J Cardiol 82:18N–28N

    Article  PubMed  CAS  Google Scholar 

  2. Lévy S, Camm AJ, Saksena S et al (2003) International consensus on nomenclature and classification of atrial fibrillation. A collaborative project of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Europace 5:119–122

    Article  PubMed  Google Scholar 

  3. Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833

    PubMed  CAS  Google Scholar 

  4. Van Gelder IC, Hagens VA, Bosker HA et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840

    Article  PubMed  Google Scholar 

  5. Alboni P, Botto GL, Bladi N et al (2004) Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 351:2384–2391

    Article  PubMed  CAS  Google Scholar 

  6. Fuster V, Ryden LE, Cannon DS et al (2006) ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary. Eur Heart J 27:1979–2030

    Article  PubMed  Google Scholar 

  7. Young-Xu Y, Jabbour S, Goldberg R et al (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92:1379–1383

    Article  PubMed  CAS  Google Scholar 

  8. Maggioni AP, Latini R, Carson PE et al for the Val-HeFT Investigators (2003) Valsartan reduces the incidence of atrial fibrillation in the patient with heart failure in the Val-HeFT trial. Circulation 108:2314

    Google Scholar 

  9. Kumagai K, Nakashima H, Urata H et al (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. J Am Coll Cardiol 41:2197–2204

    Article  PubMed  CAS  Google Scholar 

  10. Madrid AH, Bueno MG, Rebollo JMG et al (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331–336

    Article  PubMed  CAS  Google Scholar 

  11. Pedersen OD, Bagger H, Kober L et al, On behalf of the TRACE Study Group (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376–380

    PubMed  CAS  Google Scholar 

  12. Patten M, Meinertz T (2005) Medikamentöse antiarrhythmische Therapie – aktuelle Aspekte. Dtsch Med Wochenschr 130:1325–1329

    Article  PubMed  CAS  Google Scholar 

  13. Lewalter T, Lüderitz B (2005) Vorhofflimmern und Vorhofflattern – Konservative vs. Interventionelle Therapie. Kardiologie up2date 1:117–132

    Article  Google Scholar 

  14. Wang TJ, Parise H, Levy D et al (2004) Obesity and the risk of new-onset atrial fibrillation. JAMA 292:2471–2477

    Article  PubMed  CAS  Google Scholar 

  15. Lüderitz B (2006) Vorhofflimmern: Therapeutische Möglichkeiten. Med Klin 101(Sondernr 1):147–149

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B. Lüderitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lüderitz, B. Rationale und rationelle Behandlung des Vorhofflimmerns. Clin Res Cardiol Suppl 3, 95–100 (2008). https://doi.org/10.1007/s11789-008-0043-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11789-008-0043-y

Schlüsselwörter

Key words

Navigation